GlassScriptPhysician profile
Angela Kemp
NPI 1942632427
$4,710.39
in general payments reported to CMS, 2019-2025
35 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $845 · 2022: $1,040 · 2023: $893 · 2024: $919 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,695 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,694.57 |
| Education | $129.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $634.31 | 2021-2025 | |
| Abbott Laboratories | $485.51 | 2021-2025 | Freestyle Libre 3 |
| Abbvie INC. | $475.54 | 2021-2025 | |
| Novo Nordisk INC | $458.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $390.19 | 2021-2023 | Farxiga |
| Glaxosmithkline, LLC. | $323.11 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $241.68 | 2021-2025 | Repatha, Otezla, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $182.51 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.08 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $134.20 | 2021-2025 | |
| Pfizer INC. | $119.22 | 2023-2025 | |
| Astellas Pharma US INC | $113.45 | 2023-2025 | Veozah |
| Lilly USA, LLC | $95.43 | 2021-2025 | Jardiance |
| Verity Pharmaceuticals INC. | $93.02 | 2024-2025 | Tlando |
| Merck Sharp & Dohme LLC | $91.17 | 2021-2022 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Kemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.